Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 934 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Orthomyxoviridae Infection Clear all

Conditions: Influenza
Interventions: Flufirvitide 3, Placebo for Flufirvitide-3; Drug
Lead sponsor: Autoimmune Technologies, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Influenza
Interventions: DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra); Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 42
States / cities: Carmichael, California • Chula Vista, California • La Mesa, California + 39 more

Conditions: Avian Influenza, Virus Diseases
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza, Vaccine Hesitancy
Interventions: Text messaging; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 6 Months and older
Enrollment: 228,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza, COVID-19
Interventions: Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 8,795 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 106
States / cities: Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more

Conditions: Influenza, Human
Interventions: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 1,778 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Mobile, Alabama • Anaheim, California • Redding, California + 17 more

Conditions: Influenza
Interventions: High-Fiber Diet (HFD), Prebiotic Food-Enriched Diet (PreFED); Dietary Supplement
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Viral Vaccines
Interventions: Inactivated influenza vaccine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: Influenza virus vaccine (2004-2005 Formulation); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 2 Months to 9 Months
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 8
States / cities: Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 5 more

Conditions: Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation, Respiratory Failure Patients Treated With ECMO, Respiratory Failure, ICU, Ventilator Induced Lung Injury
Interventions: Personalized Positive End-Expiratory Pressure (PEEP); Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Influenza, Influenza-like Illness
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more

Conditions: Influenza
Interventions: Inactivated influenza vaccine, Placebo; Biological · Other
Lead sponsor: Mark Prausnitz; Other
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis, COVID-19, Depression, Parosmia, Hyposomia, Normosomia, Anosmia
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza
Interventions: Pumarix™, Pandemrix ™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 780 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more

Conditions: Influenza, COVID-19
Interventions: Provider communication training; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 24,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo, Oseltamivir; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Influenza -Like Illness, Influenza, Human
Interventions: Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1,989 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza, Healthy
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 10 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Avian Influenza Studies In Lebanon

Precision Vaccine Promotion in Underserved Populations

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Impact of High Dietary Fiber on Microbiome and Vaccine Responses

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Flu Vaccine Responses in the Setting of Melanoma Treatment

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Personalized Ventilator Settings for Patients on ECMO

Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III

Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

Patient-Centered Practical Vaccine Talk For Busy Clinicians

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

Recombinant Influenza Vaccination in U.S. Nursing Homes

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines